Bridgebio Pharma Inc (BBIO)

Apr 22, 2025, 7:30 AM EDT - 9 hours ago

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

Apr 11, 2025, 4:01 PM EDT - 11 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 10:00 AM EDT - 22 days ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Mar 27, 2025, 3:20 PM EDT - 26 days ago

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

AZN

Mar 27, 2025, 7:00 AM EDT - 26 days ago

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

Mar 24, 2025, 7:30 AM EDT - 4 weeks ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Mar 17, 2025, 4:01 PM EDT - 5 weeks ago

BridgeBio Announces CFO Succession

Feb 26, 2025, 2:49 AM EST - 7 weeks ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Feb 24, 2025, 4:09 PM EST - 2 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Feb 20, 2025, 1:34 PM EST - 2 months ago

BridgeBio: Strong Start For Attruby

Feb 20, 2025, 7:30 AM EST - 2 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

Feb 13, 2025, 4:01 PM EST - 2 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

Feb 11, 2025, 9:21 AM EST - 2 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Jan 21, 2025, 6:06 AM EST - 3 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BSX ISRG ITCI

Jan 15, 2025, 9:30 AM EST - 3 months ago

BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval

Jan 14, 2025, 3:40 PM EST - 3 months ago

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

Jan 13, 2025, 11:00 AM EST - 3 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

Jan 8, 2025, 11:13 AM EST - 3 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BMY IOVA LLY MDGL MRK PFE

Jan 8, 2025, 7:30 AM EST - 3 months ago

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

Dec 13, 2024, 7:18 AM EST - 4 months ago

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Dec 3, 2024, 8:00 AM EST - 5 months ago

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology

Nov 25, 2024, 9:03 AM EST - 5 months ago

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

PFE

Nov 24, 2024, 3:48 PM EST - 5 months ago

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 22, 2024, 7:25 PM EST - 5 months ago

US FDA approves BridgeBio's drug for rare heart condition

Nov 22, 2024, 7:11 PM EST - 5 months ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Nov 19, 2024, 2:44 PM EST - 5 months ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Nov 18, 2024, 11:15 AM EST - 5 months ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

Nov 18, 2024, 8:00 AM EST - 5 months ago

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

Nov 18, 2024, 5:30 AM EST - 5 months ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

Nov 14, 2024, 10:41 AM EST - 5 months ago

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

Nov 5, 2024, 7:30 AM EST - 6 months ago

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management

Oct 30, 2024, 8:00 AM EDT - 6 months ago

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

Oct 24, 2024, 7:30 AM EDT - 6 months ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

Oct 3, 2024, 7:30 AM EDT - 7 months ago

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

Sep 30, 2024, 1:17 PM EDT - 7 months ago

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

Sep 30, 2024, 7:30 AM EDT - 7 months ago

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Sep 27, 2024, 6:00 PM EDT - 7 months ago

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

Sep 17, 2024, 7:30 AM EDT - 7 months ago

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

Sep 10, 2024, 5:09 PM EDT - 7 months ago

BridgeBio to stop development of therapy for genetic disorder

Sep 10, 2024, 4:45 PM EDT - 8 months ago

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Sep 10, 2024, 4:45 PM EDT - 8 months ago

BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

Sep 9, 2024, 8:00 AM EDT - 8 months ago

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

Aug 31, 2024, 8:00 AM EDT - 8 months ago

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Aug 30, 2024, 10:50 AM EDT - 8 months ago

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

Aug 29, 2024, 7:30 AM EDT - 8 months ago

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

Aug 28, 2024, 7:30 AM EDT - 8 months ago

BridgeBio Pharma to Participate in September Investor Events

Aug 26, 2024, 7:30 AM EDT - 8 months ago

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

Aug 22, 2024, 3:15 PM EDT - 8 months ago

BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum

Aug 19, 2024, 7:30 AM EDT - 8 months ago

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

Aug 17, 2024, 2:57 AM EDT - 8 months ago

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon